Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19.

Yijia LiLinda J HarrisonKara W ChewJudy S CurrierDavid A WohlEric S DaarTeresa H EveringRyan WuMark GigantiJustin RitzArzhang Cyrus JavanRobert CoombsCarlee MoserMichael D HughesJoseph J EronDavey M SmithJonathan Z Li

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Acute COVID-19 symptoms limit daily activities, but little is known about its association with SARS-CoV-2 viral burden. In this exploratory analysis of placebo recipients in the ACTIV-2/A5401 platform trial, we showed that high anterior nasal (AN) RNA levels and detectable plasma RNA were associated with delayed symptom improvement.

Keyphrases

sars cov
phase iii
respiratory syndrome coronavirus
study protocol
clinical trial
liver failure
nucleic acid
respiratory failure
open label
randomized controlled trial
intensive care unit
double blind
sleep quality
depressive symptoms
extracorporeal membrane oxygenation
acute respiratory distress syndrome